The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This stock page is the Follow view. The Build view lets your agent query XLO owners, fund changes, insider filings, and source links through REST or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/XLO"
Use Arkolith to show who owns XLO, which funds added or reduced it, and which SEC filings prove each claim.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Bain Capital Life Sciences Investors, LLC | $5.6M | 664K | ▼−91% Reduced · −6.7M sh | Q1 2026 | |
| 2 | Frazier Life Sciences Management, L.P. | $3.6M | 423K | ▼−93% Reduced · −5.5M sh | Q1 2026 | |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $1.0M | 124K | ▲New +124K sh | Q1 2026 | |
| 4 | MORGAN STANLEY | $484K | 57K | ▼−93% Reduced · −782K sh | Q1 2026 | |
| 5 | RENAISSANCE TECHNOLOGIES LLC | $417K | 50K | ▼−86% Reduced · −295K sh | Q1 2026 | |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | $313K | 37K | ▼−89% Reduced · −292K sh | Q1 2026 | |
| 7 | FMR LLC | $307K | 37K | ▼−93% Reduced · −475K sh | Q1 2026 | |
| 8 | VANGUARD FIDUCIARY TRUST CO | $239K | 28K | ▲New +28K sh | Q1 2026 | |
| 9 | Ghisallo Capital Management LLC | $116K | 14K | ▼−99% Reduced · −1.1M sh | Q1 2026 | |
| 10 | STATE STREET CORP | $112K | 13K | ▼−93% Reduced · −173K sh | Q1 2026 | |
| 11 | CWM, LLC | $35K | 4K | ▲New +4K sh | Q1 2026 | |
| 12 | UBS Group AG | $34K | 4K | ▲20× Added · +4K sh | Q1 2026 | |
| 13 | JPMORGAN CHASE & CO | $2K | 240 | ▲New +240 sh | Q1 2026 | |
| 14 | ROYAL BANK OF CANADA | $1K | 91 | ▲New +91 sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jun 11, 2026 | Shannon James Samuel | Director | Grant (A) | 5K | $0 |
| Jun 11, 2026 | Curran Daniel J. | Director | Grant (A) | 5K | $0 |
| Jun 11, 2026 | ROSS ROBERT W. | Director | Grant (A) | 5K | $0 |
| Jun 11, 2026 | Xu Yuan | Director | Grant (A) | 5K | $0 |
| Jun 11, 2026 | Bonstein Sara | Director | Grant (A) | 5K | $0 |
| Jun 11, 2026 | Brennan Aoife | Director | Grant (A) | 5K | $0 |
| Jun 11, 2026 | Bello Akintunde Olatokumbo | Director | Grant (A) | 5K | $0 |
| Mar 26, 2026 | Shannon James Samuel | Director | Buy (P) | 5K | $44K |
| Feb 13, 2026 | GILEAD SCIENCES, INC. | 10% Owner | Buy (P) | 3.7M | $2.0M |
| Jan 2, 2026 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Sell (S) | 2K | $1K |
| Jan 2, 2026 | Frankenfield Christopher James | Chief Financial Officer | Sell (S) | 7K | $4K |
| Jan 1, 2026 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Option exercise (M) | 5K | $0 |
| Company | Co-held by | Combined value |
|---|---|---|
| DISC MEDICINE INCIRON | 3 funds | $87.3M |
| MIRUM PHARMACEUTICALS INCMIRM | 2 funds | $709.5M |
| NVIDIA CORPNVDA | 2 funds | $701.8M |
| NEWAMSTERDAM PHARMA CO NVNAMS | 2 funds | $542.4M |
| MICROSOFT CORPMSFT | 2 funds | $531.7M |
| ERASCA INCERAS | 2 funds | $399.8M |
| BRIDGEBIO PHARMA INCBBIO | 2 funds | $256.5M |
| TESLA INCTSLA | 2 funds | $255.9M |
| ARCUTIS BIOTHERAPEUTICS INCARQT | 2 funds | $233.1M |
| MEDLINE INC-CL AMDLN | 2 funds | $202.3M |
| MBX BIOSCIENCES INCMBX | 2 funds | $198.6M |
| PHATHOM PHARMACEUTICALS INCPHAT | 2 funds | $138.5M |
Ranked by how many of XLO's institutional holders also hold each name, a cross-fund conviction signal. Via the MCP server (ticker.co_held).
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for XLO. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes. Every panel above is one call to the Arkolith API & MCP server.